Feraheme
Payments companies reported to CMS as associated with Feraheme. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Feraheme, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Feraheme
These are the largest totals companies reported as associated with Feraheme. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Csanad Varallyay | Portland, OR | Diagnostic Radiology | $69,071.60 |
| Dennis Fisher | San Francisco, CA | $56,350.00 | |
| Bradley Warady | Kansas City, MO | Pediatric Nephrology | $1,500.00 |
| Mukesh Harisinghani | Boston, MA | Diagnostic Radiology | $164.51 |
| John Finn | Los Angeles, CA | Diagnostic Radiology | $164.51 |
Prescribed Feraheme?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.